Le Lézard
Classified in: Health
Subjects: NPT, TDS, HSP, WOM, BLK, FVT

Women of Color in Pharma Marks Official Launch with First Annual Conference


SOMERSET, N.J., Oct. 5, 2017 /PRNewswire/ -- Women of Color in Pharma (WOCIP) today announced that its official launch will take place at the WOCIP first annual conference, scheduled for Sunday, November 5 and Monday, November 6, 2017 in Princeton, N.J. WOCIP is a professional society focused on fostering the growth and development of Black and Latina women in the pharmaceutical industry. WOCIP enables the cultivation of a sustainable pipeline of Black and Latina women leaders who, together, can harness the power of their diverse expertise, bringing a competitive advantage to industry.

"WOCIP's vision is to enable the transformation of the pharmaceutical professional landscape with women of color," said co-founder Charlotte Jones-Burton, M.D., M.S. "Our mission is to empower women of color in pharma to excel in their personal and professional development and to transform their pathway within the pharmaceutical industry."

Speakers at the first annual conference include representatives from pharmaceutical companies and contract research organizations. Wanda Bryant Hope, Chief Diversity Officer for Johnson & Johnson, will deliver the keynote address. Other speakers include Michelle Amador of Covance, Marisa Co of Bristol-Myers Squibb, Cristina Santos of Sanofi, and Celeste Warren of Merck. The conference is co-sponsored by Bristol-Myers Squibb and Novo Nordisk, with generous support from Covance.

"The conference theme is 'Get Inspired. Be Empowered,'" said co-founder Patricia Cornet, M.A. "We welcome colleagues in the pharmaceutical industry who are interested in engaging in professional development, networking and discussing key areas that are shaping the pharmaceutical landscape for WOCIP to join us."  

The Conference opens with a welcome reception on Sunday, November 5 at 6 p.m. at the Hyatt Regency in Princeton, N.J. The full-day conference is Monday, November 6 at 8 a.m. at the Novo Nordisk Inc. training facility in Princeton, N.J. To register, visit the WOCIP website http://wocip.org/conferences/

About Women of Color in Pharma (WOCIP)

Women of Color in Pharma (WOCIP) is a 501(c) (6) non-profit corporation whose purpose is to promote the development and advancement of women of color who are employed in the pharmaceutical industry. Founded in March 2015 by Charlotte Jones-Burton, M.D., M.S. and Patricia Cornet, M.A., WOCIP has an informal network of approximately 500 members and is supported by member dues and corporate sponsors. For more information, please visit http://wocip.org/.

Jill Vitiello
Vitiello Communications Group
O: 732-238-6622 ext. 501
M: 908-420-3506

SOURCE Women of Color in Pharma


These press releases may also interest you

at 17:33
The American Association of Kidney Patients (AAKP), the oldest and largest independent kidney patient consumer organization in the United States, announced the overwhelming success of its 2024 "Are You O-K+" campaign, which marked May 1 (5.1) as...

at 17:21
The Jackson Laboratory (JAX), an independent, nonprofit biomedical research organization, and AbTherx, an innovator in biotechnology, announced a strategic partnership to develop and commercialize cutting-edge tools to expedite antibody discovery and...

at 17:00
Zepp Health Corporation ("Zepp" or the "Company") , a global leader in smart wearables and health technology, today announced that it has received a letter from the New York Stock Exchange (the "NYSE") dated April 30, 2024, notifying Zepp that it is...

at 16:55
Revelation Biosciences, Inc. (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March...

at 16:55
Maple Counseling has partnered with Saban Community Clinic to launch the Saban Partnership Program, aimed at enhancing access to mental healthcare for underserved communities. This initiative includes the introduction of four bilingual Associate...

at 16:35
Bristol Myers Squibb today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC). CheckMate -73L evaluated...



News published on and distributed by: